ClinicalTrials.gg
CompletedNCT05138796Updated Aug 3, 2022

A Pharmacokinetic Study of TP-05 in Healthy Subjects

A Phase 1 interventional study of TP-05 (lotilaner oral capsules) and Placebo in Healthy, sponsored by Tarsus Pharmaceuticals, Inc.. Completed at 1 site in United States. Open to participants aged 18 Years to 59 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2022-08-03.

Sponsored by Tarsus Pharmaceuticals, Inc. · Phase 1, Interventional, and Basic science

From the registry’s dates

  • Primary completion was Mar 2022, 4 years 7 months ago, and no results have been posted to the registry.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
67
Allocation
Randomized
Ages
18 Years to 59 Years
Sex
All
01

Study summary

A Phase 1, Randomized, Double-Blind, Single- and Multiple-Ascending Dose Study Evaluating the Safety, Tolerability, Food-Effect and Pharmacokinetics of TP-05 in Healthy Subjects

Read the detailed description

This Phase 1 study is a randomized, double-blind, single- and multiple-ascending dose trial to evaluate the safety, tolerability, food-effect, and pharmacokinetics of TP-05 in healthy subjects. Subjects will be enrolled in 5 sequential, ascending single dose cohorts and 3 multiple, ascending dose cohorts. Dose escalation will be approved by a safety monitoring committee before beginning the next cohort. The Safety Review Committee (SRC) will evaluate if any dose-limiting adverse events (AEs) through Day 15 (in Cohorts 1-5) or through Day 36 (in Cohorts 6-8) occurred in a cohort before proceeding to dosing in the next dose level. In addition, the SRC will review selected PK parameters after selected cohorts. Skin punch biopsies, and venous, capillary, and urine samples may be collected at various timepoints for pharmacokinetic analysis. Safety assessments include monitoring of adverse events, clinical laboratory testing, vital sign measurements, physical examinations, and ECGs. A blood sample may also be collected to evaluate tick mortality upon exposure.

02

Conditions studied

  • Healthy
03

In context

Lead sponsor

Tarsus Pharmaceuticals, Inc. is the lead sponsor of 13 studies on the registry; 2 are open to participants now.

Of its 8 completed or terminated interventional studies of FDA-regulated products, 3 (38%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 59 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Provision of signed and dated form (ICF)
  2. Have no diseases captured in the medical history or evidence of clinically significant findings on the physical examination (including vital signs) and/or , as determined by an investigator

Exclusion criteria

Exclusion Criteria:

  1. Female who is pregnant or lactating
  2. Presence or history of significant gastrointestinal, metabolic, liver or kidney disease, or surgery that may affect drug bioavailability (excluding appendectomy and cholecystectomy)
  3. History of significant cardiovascular, pulmonary, hematologic, neurological, psychiatric, endocrine, immunologic, or dermatologic disease
  4. Have a history of a (or active malignancy), with the exception of treated basal cell or squamous cell carcinoma
  5. Use of any prescription drugs (with the exception of hormonal or hormone replacement therapy) within 14 days prior to or use of any over-the-counter drugs in the 7 days prior to the first study drug administration
  6. Positive urine alcohol test result and/or drugs of abuse at Screening or prior to the first drug administration (including cotinine, cannabinoids, amphetamines, barbiturates, cocaine, opiates, phencyclidine and benzodiazepines)
  7. Positive test results for -1/HIV-2 Antibodies, surface Antigen (HBsAg) or Antibody (HCVAb)
  8. Treatment with an drug within 30 days or 5 times the half-life (whichever is longer) prior to Screening
  9. Blood donation (excluding plasma donation) of approximately 500 mL within 56 days prior to Screening
  10. Plasma donation within 7 days prior to screening
Terms in these criteria, in plain language(9)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 1
Primary purpose
Basic science
Allocation
Randomized
Intervention model
Sequential assignment
Masking
Triple (Participant, Investigator, Outcomes assessor)
Enrollment
67 participants (actual)

Study arms

  • Experimental
    TP-05 SAD

    Single dose of TP-05 (lotilaner oral capsules) at 4 dose levels in ascending order

    Drug: TP-05 (lotilaner oral capsules)

  • Experimental
    Placebo SAD

    Single dose of Placebo

    Drug: Placebo

  • Experimental
    TP-05 MAD

    Four doses of TP-05 (lotilaner oral capsules) at 3 dose levels in ascending order

    Drug: TP-05 (lotilaner oral capsules)

  • Experimental
    Placebo MAD

    Four doses of Placebo

    Drug: Placebo

  • Experimental
    TP-05 Fasted

    Single dose of TP-05 (lotilaner oral capsules) in a fasted state

    Drug: TP-05 (lotilaner oral capsules)

  • Experimental
    Placebo Fasted

    Single dose of placebo in a fasted state

    Drug: Placebo

Interventions

06

What researchers measure

Primary outcomes

  1. Incidence of treatment emergent adverse events (TEAEs)

    Evaluate the safety of TP-05 through the incidence rate of TEAEs

    Time frame: up to 151 days

  2. Clinically significant changes from Baseline chemistry laboratory tests

    Evaluate the safety of TP-05 through clinically significant changes from Baseline chemistry laboratory tests

    Time frame: up to 151 days

  3. Clinically significant changes from Baseline hematology laboratory tests

    Evaluate the safety of TP-05 through clinically significant changes from Baseline hematology laboratory tests

    Time frame: up to 151 days

  4. Clinically significant changes from Baseline general appearance

    Evaluate the safety of TP-05 through clinically significant changes from Baseline general appearance

    Time frame: up to 151 days

  5. Clinically significant changes from Baseline physical examination of head, ears, nose, and throat

    Evaluate the safety of TP-05 through clinically significant changes from Baseline physical examinations of head, ears, nose, and throat

    Time frame: up to 151 days

  6. Clinically significant changes from Baseline physical examination of neck (thyroid)

    Evaluate the safety of TP-05 through clinically significant changes from Baseline physical examinations of neck (thyroid)

    Time frame: up to 151 days

  7. Clinically significant changes from Baseline physical examination of respiratory system

    Evaluate the safety of TP-05 through clinically significant changes from Baseline physical examinations of respiratory system

    Time frame: up to 151 days

  8. Clinically significant changes from Baseline physical examination of cardiovascular system

    Evaluate the safety of TP-05 through clinically significant changes from Baseline physical examinations of cardiovascular system

    Time frame: up to 151 days

  9. Clinically significant changes from Baseline physical examination of gastrointestinal system

    Evaluate the safety of TP-05 through clinically significant changes from Baseline physical examinations of gastrointestinal system

    Time frame: up to 151 days

  10. Clinically significant changes from Baseline physical examination of neurological system

    Evaluate the safety of TP-05 through clinically significant changes from Baseline physical examinations of neurological system

    Time frame: up to 151 days

  11. Clinically significant changes from Baseline physical examination of musculoskeletal system (extremities)

    Evaluate the safety of TP-05 through clinically significant changes from Baseline physical examination of musculoskeletal system (extremities)

    Time frame: up to 151 days

  12. Clinically significant changes from Baseline physical examination of skin

    Evaluate the safety of TP-05 through clinically significant changes from Baseline physical examination of skin

    Time frame: up to 151 days

  13. Clinically significant changes from Baseline vital signs

    Evaluate the safety of TP-05 through clinically significant changes from Baseline vital signs (including temperature \[degrees Celsius\], pulse rate \[beats per minute\], respiration rate \[breaths per minute\], and changes in systolic and diastolic blood pressure \[mmHg\])

    Time frame: up to 151 days

  14. Clinically significant changes from Baseline vital signs (temperature [degrees Celsius])

    Evaluate the safety of TP-05 through clinically significant changes from Baseline vital signs including temperature \[degrees Celsius\]

    Time frame: up to 151 days

  15. Clinically significant changes from Baseline vital signs (pulse rate [beats per minute])

    Evaluate the safety of TP-05 through clinically significant changes from Baseline vital signs including pulse rate \[beats per minute\]

    Time frame: up to 151 days

  16. Clinically significant changes from Baseline vital signs (respiration rate [breaths per minute])

    Evaluate the safety of TP-05 through clinically significant changes from Baseline vital signs including respiration rate \[breaths per minute\]

    Time frame: up to 151 days

  17. Clinically significant changes from Baseline vital signs (systolic and diastolic blood pressure [mmHg])

    Evaluate the safety of TP-05 through clinically significant changes from Baseline vital signs including changes in systolic and diastolic blood pressure \[mmHg\])

    Time frame: up to 151 days

  18. Clinically significant changes from Baseline electrocardiograms (ECGs)

    Evaluate the safety of TP-05 through clinically significant changes from Baseline ECGs (including changes in mean ventricular rate \[beats/min\], pulse rate \[msec\], QRS duration \[msec\], QT interval \[msec\], QTcF interval \[msec\])

    Time frame: up to 151 days

Secondary outcomes

  1. Exposure and PK of lotilaner in whole blood

    PK parameters for whole blood sampling methods following dose administration will be evaluated and include Cmax at various times

    Time frame: up to 151 days

  2. Exposure and PK of lotilaner in whole blood

    PK parameters for whole blood sampling methods following dose administration will be evaluated and include Tmax at various times

    Time frame: up to 151 days

  3. Exposure and PK of lotilaner in whole blood

    PK parameters for whole blood sampling methods following dose administration will be evaluated and include Tlag at various times

    Time frame: up to 151 days

  4. Exposure and PK of lotilaner in whole blood

    PK parameters for whole blood sampling methods following dose administration will be evaluated and include AUC0-168 at various times

    Time frame: up to 151 days

  5. Exposure and PK of lotilaner in whole blood

    PK parameters for whole blood sampling methods following dose administration will be evaluated and include AUC0-2880 at various times

    Time frame: up to 151 days

  6. Exposure and PK of lotilaner in whole blood

    PK parameters for whole blood sampling methods following dose administration will be evaluated and include AUC0-t at various times

    Time frame: up to 151 days

  7. Exposure and PK of lotilaner in whole blood

    PK parameters for whole blood sampling methods following dose administration will be evaluated and include AUC0-inf at various times

    Time frame: up to 151 days

  8. Exposure and PK of lotilaner in whole blood

    PK parameters for whole blood sampling methods following dose administration will be evaluated and include CL/F at various times

    Time frame: up to 151 days

  9. Exposure and PK of lotilaner in whole blood

    PK parameters for whole blood sampling methods following dose administration will be evaluated and include Vz/F at various times

    Time frame: up to 151 days

  10. Exposure and PK of lotilaner in whole blood

    PK parameters for whole blood sampling methods following dose administration will be evaluated and include eff at various times

    Time frame: up to 151 days

  11. Exposure and PK of lotilaner in whole blood

    PK parameters for whole blood sampling methods following dose administration will be evaluated and include Thalf at various times

    Time frame: up to 151 days

  12. Exposure and PK of lotilaner in whole blood

    PK parameters for whole blood sampling methods following dose administration will be evaluated and include λz at various times

    Time frame: up to 151 days

  13. Exposure and PK of lotilaner in whole blood

    PK parameters for whole blood sampling methods following dose administration will be evaluated and include AUC%extrap at various times

    Time frame: up to 151 days

  14. Exposure and PK of lotilaner in whole blood

    PK parameters for whole blood sampling methods following dose administration will be evaluated and include MRT0-t at various times

    Time frame: up to 151 days

  15. Exposure and PK of lotilaner in whole blood

    PK parameters for whole blood sampling methods following dose administration will be evaluated and include Rac at various times

    Time frame: up to 151 days

  16. Exposure and PK of lotilaner in whole blood

    PK parameters for whole blood sampling methods following dose administration will be evaluated and include Ctrough at various times

    Time frame: up to 151 days

  17. Urine exposure and renal PK of lotilaner

    PK parameters for urine sampling methods will be evaluated and include Ae.

    Time frame: 3 days

  18. Urine exposure and renal PK of lotilaner

    PK parameters for urine sampling methods will be evaluated and include fe.

    Time frame: 3 days

  19. Urine exposure and renal PK of lotilaner

    PK parameters for urine sampling methods will be evaluated and include CLr0-48.

    Time frame: 3 days

  20. Impact of fasting on the PK of lotilaner

    PK parameters will be evaluated for lotilaner following dosing with food and under fasting conditions. Parameters include Cmax at various times

    Time frame: up to 151 days

  21. Impact of fasting on the PK of lotilaner

    PK parameters will be evaluated for lotilaner following dosing with food and under fasting conditions. Parameters include Tmax at various times

    Time frame: up to 151 days

  22. Impact of fasting on the PK of lotilaner

    PK parameters will be evaluated for lotilaner following dosing with food and under fasting conditions. Parameters include Tlag at various times

    Time frame: up to 151 days

  23. Impact of fasting on the PK of lotilaner

    PK parameters will be evaluated for lotilaner following dosing with food and under fasting conditions. Parameters include AUC0-168 at various times

    Time frame: up to 151 days

  24. Impact of fasting on the PK of lotilaner

    PK parameters will be evaluated for lotilaner following dosing with food and under fasting conditions. Parameters include AUC0-2880 at various times

    Time frame: up to 151 days

  25. Impact of fasting on the PK of lotilaner

    PK parameters will be evaluated for lotilaner following dosing with food and under fasting conditions. Parameters include AUC0-t at various times

    Time frame: up to 151 days

  26. Impact of fasting on the PK of lotilaner

    PK parameters will be evaluated for lotilaner following dosing with food and under fasting conditions. Parameters include AUC0-inf at various times

    Time frame: up to 151 days

  27. Impact of fasting on the PK of lotilaner

    PK parameters will be evaluated for lotilaner following dosing with food and under fasting conditions. Parameters include CL/F at various times

    Time frame: up to 151 days

  28. Impact of fasting on the PK of lotilaner

    PK parameters will be evaluated for lotilaner following dosing with food and under fasting conditions. Parameters include Vz/F at various times

    Time frame: up to 151 days

  29. Impact of fasting on the PK of lotilaner

    PK parameters will be evaluated for lotilaner following dosing with food and under fasting conditions. Parameters include Thalf at various times

    Time frame: up to 151 days

  30. Impact of fasting on the PK of lotilaner

    PK parameters will be evaluated for lotilaner following dosing with food and under fasting conditions. Parameters include λz at various times

    Time frame: up to 151 days

  31. Impact of fasting on the PK of lotilaner

    PK parameters will be evaluated for lotilaner following dosing with food and under fasting conditions. Parameters include AUC%extrap at various times

    Time frame: up to 151 days

  32. Impact of fasting on the PK of lotilaner

    PK parameters will be evaluated for lotilaner following dosing with food and under fasting conditions. Parameters include MRT0-t at various times

    Time frame: up to 151 days

  33. Impact of fasting on the PK of lotilaner

    PK parameters will be evaluated for lotilaner following dosing with food and under fasting conditions. Parameters include Rac at various times

    Time frame: up to 151 days

  34. Impact of fasting on the PK of lotilaner

    PK parameters will be evaluated for lotilaner following dosing with food and under fasting conditions. Parameters include Ctrough at various times

    Time frame: up to 151 days

07

Study locations

1 site
  • Altasciences
    Overland Park, Kansas 66212, United States
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from May 2021 to primary completion in Mar 2022, 10 months.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 22, 2021
First posted
Dec 1, 2021
StartActual
May 6, 2021
Primary completionActual
Mar 25, 2022
CompletionActual
Jul 25, 2022
Last update
Aug 3, 2022
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 3, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05138796
Lead sponsor
Tarsus Pharmaceuticals, Inc.
Responsible party
Sponsor
First posted
Dec 1, 2021
Start date
May 6, 2021
Primary completion
Mar 25, 2022
Completion
Jul 25, 2022
Last update
Aug 3, 2022

Study contacts

Jeremy Lim
study director · Tarsus Pharmaceuticals

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Lotilaner

Start the discussion